GROWTH
Top line stable.
+16.3% YoY versus +16.2% prior. 3y CAGR +14.0%.
+16.3%
Veeva Systems Inc. VEEV
Healthcare · Market Cap: $25.9B
$153.30▼ 1.55 (1.00%)
Fundamentals as of 2026-04-30
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $25.9B
Fundamentals as of 2026-04-30
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
1 of 2 legendary models say BUY VEEV — but Peter Lynch disagrees.
What would legendary investors pay for VEEV?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
+16.3% YoY versus +16.2% prior. 3y CAGR +14.0%.
+16.3%Net margin 28.4% versus 26.0% prior (+2.4pp). Operating 28.7% — gap is tight.
28.4%P/E 30.8x — 47% below the 5y median of 57.9x. Forward 19.3x hints at EPS expansion next year.
30.8xBottom line: VEEV splits the legendary models — 1 BUY, 0 HOLD, 1 AVOID, but earns a B sector grade (64/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
Concerns — Veeva Systems Inc.'s 12.9% ROE is below sector median.
Financial story
Concerns — Veeva Systems Inc.'s 12.9% ROE and 0.25 debt-to-equity warrant a closer look at the underlying business.
Buffett and Lynch evaluate VEEV against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
VEEV's P/E ratio is 30.8x. 5-year P/E history is in the financials tab.
1 of 2 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
VEEV's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
VEEV is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
1 of 2 legendary investor models rate VEEV a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
How does VEEV compare?
See exactly where VEEV ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingVEEV sits at #10 in Healthcare with a B grade (64/100).
